The Path raised $14.3 million in seed funding to build an AI therapy app designed to avoid the safety pitfalls of consumer chatbots, the company announced today. Prime Movers Lab led the round, with participation from Olympic speed skater Apolo Anton Ohno, boxer Deontay Wilder, and Designer Fund. Motivational speaker Tony Robbins joined as co-founder after initially advising on branding.
The startup emerged from Mental, a men's mental health app where co-founders Anson Whitmer and Tyler Sheaffer noticed AI interactive audio resonating with users. Whitmer, an early Calm employee who left in 2021, says the app's post-trained model scored 95 on the Vera-MH mental health safety benchmark. Consumer bots top out at 65 on the same test.
Robbins shaped The Path into a therapy-plus-coaching product that integrates his self-improvement methods. The app currently offers 11 virtual AI therapists, each customizable for directness and other behavioral traits. Users can select a therapist and adjust session parameters based on whether they want confrontation or support.
Key facts
- 01The Path raised $14.3M in seed funding led by Prime Movers Lab, with Tony Robbins joining as co-founder.
- 02The startup's AI model scored 95 on the Vera-MH mental health safety benchmark versus a 65 top score for consumer chatbots.
- 03OpenAI reports at least 900 people use ChatGPT for mental health queries every week.
- 04The app offers 11 virtual AI therapists and plans to charge $40 per month when it exits beta.
- 05Co-founder Anson Whitmer previously worked at Calm, leaving in 2021 to build more personalized mental health tools.
The core technical bet is that consumer chatbots optimize for engagement and quick resolution, while effective therapy requires structured exploration of underlying problems. Whitmer says The Path trains its model to dig into assumptions and help users discover their own solutions rather than reinforcing existing beliefs. The model is post-trained from open-source foundations and does not wrap the major consumer LLMs.
OpenAI has disclosed that at least 900 people use ChatGPT for mental health-related queries every week, a number that underscores demand but also raises safety questions. Whitmer argues consumer LLMs are tuned to agree with users to maintain engagement, the opposite of what therapy requires.
The app is free during its user-acquisition phase. The Path plans to charge $40 per month once it exits beta, positioning itself between meditation apps and traditional therapy in both cost and clinical depth.
Whitmer's pursuit of mental health tech stems from personal tragedy. His uncle committed suicide when Whitmer was 19, prompting him to pursue a PhD in psychology. A cousin later left a voicemail Whitmer describes as a call for help, then died by suicide before Whitmer could respond. Those experiences pushed him toward scalable interventions rather than academic research.
He spent years at Calm alongside co-founder Sheaffer but concluded meditation, while evidence-backed, could not address idiosyncratic personal problems at scale. The shortage of human therapists creates a structural gap AI might fill if trained correctly.
The challenge for The Path is proving that its safety-tuned model translates to measurably better outcomes than general-purpose chatbots without sacrificing the engagement that drives retention. Scoring 95 on Vera-MH is a benchmark win, but retention and clinical efficacy are harder to benchmark in a consumer app than in a controlled trial.
The mental health AI category is crowded with apps claiming therapeutic value, many of them wrappers over consumer LLMs with light prompt tuning. The Path's decision to post-train from open-source models rather than wrap OpenAI or Anthropic is a technical and regulatory hedge, insulating the product from changes to upstream models and clarifying liability.
Robbins's involvement brings brand recognition and a readymade methodology, but also ties the product to a polarizing public figure whose self-help empire has attracted both devoted followers and skeptics. Whether that association expands the addressable market or narrows it will show up in conversion data once paid subscriptions launch.
The broader question is whether AI therapy apps can scale beyond early adopters without triggering regulatory scrutiny. The FDA does not currently regulate most mental health chatbots as medical devices, but that could shift if adverse events accumulate or if apps begin making diagnostic claims. The Path's emphasis on coaching alongside therapy may be a hedge against that risk.
Working on something we should cover, or seeing a story we missed? Send leads, documents, or feedback to hello@aichatdaily.com. For sensitive tips, see our secure tips page for Signal and PGP options.
Spotted an error? Email hello@aichatdaily.com with the URL and the issue, or read our full corrections policy.
